Guidelines on testicular cancer
Standard
Guidelines on testicular cancer. / Albers, Peter; Albrecht, Walter; Algaba, Ferran; Bokemeyer, Carsten; Cohn-Cedermark, Gabriella; Horwich, Alan; Klepp, Olbjoern; Laguna, M Pilar; Pizzocaro, Giorgio.
in: EUR UROL, Jahrgang 48, Nr. 6, 12.2005, S. 885-94.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Guidelines on testicular cancer
AU - Albers, Peter
AU - Albrecht, Walter
AU - Algaba, Ferran
AU - Bokemeyer, Carsten
AU - Cohn-Cedermark, Gabriella
AU - Horwich, Alan
AU - Klepp, Olbjoern
AU - Laguna, M Pilar
AU - Pizzocaro, Giorgio
PY - 2005/12
Y1 - 2005/12
N2 - OBJECTIVE: To up-date the 2001 version of the EAU testicular cancer guidelines.METHODS: A non-structured literature review until January 2005 using the MEDLINE database has been performed. Literature has been classified according to evidence-based medicine levels.RESULTS: Testicular cancer is a highly curable disease. Excellent cure rates have been achieved by standardization of treatment, interdisciplinary management, and tremendous success in performing clinical trials. Currently, the aims of testicular cancer treatment are as follows: for patients with low-stage disease, a reduction in treatment is proposed to improve long-term toxicity in these patients with unaltered life expectancy; for about 10% of patients with advanced disease and poor prognosis, intensification of treatment (including high-dose chemotherapy and new drugs as well as aggressive surgical approaches) is being investigated to improve long-term cure rates.CONCLUSION: Guidelines will improve clinical practice only if they are regularly updated. This update presents the state-of-the-art management of testicular cancer patients in 2005.
AB - OBJECTIVE: To up-date the 2001 version of the EAU testicular cancer guidelines.METHODS: A non-structured literature review until January 2005 using the MEDLINE database has been performed. Literature has been classified according to evidence-based medicine levels.RESULTS: Testicular cancer is a highly curable disease. Excellent cure rates have been achieved by standardization of treatment, interdisciplinary management, and tremendous success in performing clinical trials. Currently, the aims of testicular cancer treatment are as follows: for patients with low-stage disease, a reduction in treatment is proposed to improve long-term toxicity in these patients with unaltered life expectancy; for about 10% of patients with advanced disease and poor prognosis, intensification of treatment (including high-dose chemotherapy and new drugs as well as aggressive surgical approaches) is being investigated to improve long-term cure rates.CONCLUSION: Guidelines will improve clinical practice only if they are regularly updated. This update presents the state-of-the-art management of testicular cancer patients in 2005.
KW - Adult
KW - Chemotherapy, Adjuvant
KW - Combined Modality Therapy
KW - Humans
KW - Male
KW - Middle Aged
KW - Neoplasm Staging
KW - Neoplasms, Germ Cell and Embryonal
KW - Practice Guidelines as Topic
KW - Prognosis
KW - Radiotherapy, Adjuvant
KW - Risk Assessment
KW - Survival Rate
KW - Testicular Neoplasms
KW - Treatment Outcome
KW - Urologic Surgical Procedures, Male
U2 - 10.1016/j.eururo.2005.06.019
DO - 10.1016/j.eururo.2005.06.019
M3 - SCORING: Journal article
C2 - 16126333
VL - 48
SP - 885
EP - 894
JO - EUR UROL
JF - EUR UROL
SN - 0302-2838
IS - 6
ER -